Specialised biopharmaceutical company with a focus on rare and debilitating diseases Sobi (STO:SOBI) and Enable Injections, Inc., a global healthcare innovation company developing and manufacturing an innovative wearable drug delivery platform, announced on Thursday that they have entered into an international development and distribution agreement for the enFuse Injector, aimed at delivering Aspaveli (pegcetacoplan) subcutaneously.

The enFuse Injector, produced by Enable and distributed by Sobi, is designed to simplify patients' self-administration while minimizing daily disruptions. This collaboration seeks to enhance patient comfort, adherence and overall health outcomes.

Future availability of Aspaveli with enFuse technology may offer patients a more convenient treatment option, increasing mobility and confidence. Enable's partnership with Sobi supports their mission to redefine drug delivery. Upon regulatory approval, enFuse could be the first subcutaneous delivery device of its kind outside the US.